First Trust Capital Management’s Starling Oncology STLN Stock Holding History

First Trust Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-149,344	Closed	-$1.48M	–	263
2021 Q3	$1.48M	Buy	149,344 +24,854	+20%	+$247K	0.23%	111
2021 Q2	$1.24M	Buy	124,490 +55,606	+81%	+$560K	0.18%	120
2021 Q1	$686K	Hold	68,884	–	–	0.13%	141
2020 Q4	$744K	Hold	68,884	–	–	0.21%	90
2020 Q3	$715K	Buy	+68,884	New	+$716K	0.19%	68

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

First Trust Capital Management's STLN Position: Q4 2021 in Review

First Trust Capital Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 149,344 shares — an estimated $1.48M sold.

First Trust Capital Management first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $1.48M in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

First Trust Capital Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
First Trust Capital Management sold 149,344 Starling Oncology shares in Q4 2021, an estimated $1.48M.
First Trust Capital Management first reported a position in Starling Oncology in Q3 2020 and held it in 5 quarters.
First Trust Capital Management's Starling Oncology position peaked at $1.48M in Q3 2021.
21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on First Trust Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.